The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children with eosinophilic esophagitis.
The nod makes Dupixent the first and only medicine approved in the USA specifically for this group of patients, and adds to an initial nod for patients aged 12 and over.
In a statement, developer Sanofi (Euronext: SAN) noted that the FDA undertook its assessment under the Priority Review scheme, which is reserved for medicines that represent potentially significant improvements in efficacy or safety for serious conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze